Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose

References

• Kassebaum NJ. The global burden of anemia. Hematol Oncol Clin North Am. 2016;30(2):561–308.
   PubMed Web of Science ®Google Scholar
• Tan J, He G, Qi Y, et al. Prevalence of anemia and Iron Deficiency Anemia in Chinese Pregnant Women (IRON WOMEN): a national cross-sectional survey. BMC Pregnancy Childbirth. 2020;20(1):670.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ye H, Liu J, et al. Prevalence of anemia and sociodemographic characteristics among pregnant and non-pregnant women in southwest China: a longitudinal observational study. BMC Pregnancy Childbirth. 2020;20(1):535.
   PubMed Web of Science ®Google Scholar
• Yamamoto K Wang N Takita M, et al. Iron deficiency anaemia: its prevalence among women of reproductive age in Shanghai and Tokyo and links to body mass index. Cureus. 2020;12:e9436.
   Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang J, Yuan Q, et al. Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). BMC Nephrol. 2017;18(1):311.
   PubMedGoogle Scholar
• Shen Y, Wang J, Yuan J, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life – results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2021;22(1):64.
   PubMed Web of Science ®Google Scholar
• Haalen H v, Sloand J, Moon R, et al. Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data. Kidney Res Clin Pract. 2020;39(3):318–333.
   PubMed Web of Science ®Google Scholar
• Huang Y, Su C, Jiang H, et al. The association between pretreatment anemia and overall survival in advanced non-small cell lung cancer: a retrospective cohort study using propensity score matching. J Cancer. 2022;13(1):51–61.
   PubMed Web of Science ®Google Scholar
• Kalra SK, Thilagar B, Khambaty M, et al. Post-operative anemia after major surgery: a brief review. Curr Emerg Hosp Med Rep. 2021;9:89–95.
   Web of Science ®Google Scholar
• Lin J, Wang C, Liu J, et al. Prevalence and intervention of preoperative anemia in Chinese adults: a retrospective cross-sectional study based on national preoperative anemia database. EClinicalMedicine. 2021;36:100894.
   PubMedGoogle Scholar
• DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142(1):8–12.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency. Lancet Haematol. 2020;7(4):e342–e350.
   PubMed Web of Science ®Google Scholar
• Stein J, Haas JS, Ong SH, et al. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. CEOR. 2018;10:93–103.
   Google Scholar
• Keeler BD, Simpson JA, Ng O, et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 2017;104(3):214–221.
   PubMed Web of Science ®Google Scholar
• Elhenawy AM, Meyer SR, Bagshaw SM, et al. Role of preoperative intravenous iron therapy to correct anemia before major surgery: a systematic review and meta-analysis. Syst Rev. 2021;10(1):36.
   PubMedGoogle Scholar
• Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52(1):18–29.
   PubMed Web of Science ®Google Scholar
• Hufnagel DH, Mehta ST, Ezekwe C, et al. Prevalence of anemia and compliance with NCCN guidelines for evaluation and treatment of anemia in patients with gynecologic cancer. J Natl Compr Canc Netw. 2021;19(5):513–520.
   PubMed Web of Science ®Google Scholar
• Li LJ, Zhang LS. 缺铁性贫血规范化诊治的若干问题 [considerations on the standardized diagnosis and treatment of iron-deficiency anemia]. Zhonghua Yi Xue Za Zhi. 2021;101(40):3266–3270.
   PubMedGoogle Scholar
• Li Y, Shi H, Wang W-M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine. 2016;95(24):e3872.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Jiang J, Wu S, et al. Current pattern of Chinese dialysis units: a cohort study in a representative sample of units. Chin Med J. 2012;125(19):3434–3439.
   PubMed Web of Science ®Google Scholar
• Hao C-M, Wittbrodt ET, Palaka E, et al. Understanding patient perspectives and awareness of the impact and treatment of anemia with chronic kidney disease: a patient survey in China. Int J Nephrol Renovasc Dis. 2021;14:53–64.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007–1014.
   PubMed Web of Science ®Google Scholar
• Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92(3):286–291.
   PubMed Web of Science ®Google Scholar
• Kassianides X, Bodington R, Bhandari S. An evaluation of ferric derisomaltose as a treatment for anemia. Expert Rev Hematol. 2021;14(1):7–29.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–195.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhang Y, Boegelund M, et al. PR4 health utility assessment of different options for treatment of iron deficiency anemia: results from time-trade-off study in China. Value Health. 2021;24:S197.
   Web of Science ®Google Scholar
• Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020;23(7):751–759.
   PubMed Web of Science ®Google Scholar
• Davis S, Stevenson M, Tappenden P, et al. NICE DSU Technical Support Document 15: Cost-effectiveness modelling using patient-level simulation [Internet]. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014. [cited 2022 Jan 04]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD15_Patient-level_simulation.pdf.
   Google Scholar
• IQVIA. Prescription database; 2021. Shanghai: IQVIA.
   Google Scholar
• Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104(6):1460–1467.
   PubMed Web of Science ®Google Scholar
• Global Health Observatory. Life tables by country: China. Geneva: World Health Organization; 2020.
   Google Scholar
• Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019;12(2):129–136.
   PubMed Web of Science ®Google Scholar
• Bellos I, Frountzas M, Pergialiotis V. Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis. Transfus Med Rev. 2020;34(3):188–194.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111–120.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Purchasing power parities. Paris: Organisation for Economic Co-operation and Development; 2021.
   Google Scholar
• Hu J, Fan X. Song S. 64例胺碘酮治疗老年冠心病心律不齐的临床疗效分析 [clinical efficacy analysis of 64 cases of amiodarone in the treatment of arrhythmia in elderly people with coronary heart disease]. China Med Guide. 2014;12:103–104.
   Google Scholar
• Xin Y. 高血压控制与治疗费用的观察 [observation of hypertension control and treatment costs]. Qinghai Med J. 2012;42:74–75.
   Google Scholar
• Gao D. 大剂量地塞米松治疗过敏性休克的疗效及安全性分析 [analysis of the efficacy and safety of high-dose dexamethasone in the treatment of anaphylaxis]. Chin Folk Rem. 2020;028:68–69.
   Google Scholar
• Zhang L, Liu B, Wang C. Pharmaceutical analysis of different antibiotic regimens in the treatment of lower respiratory tract infection. Exp Ther Med. 2018;16:2369–2374.
   PubMed Web of Science ®Google Scholar
• Jackson JD, Cotton SE, Bruce Wirta S, et al. Burden of heart failure on patients from China: results from a cross-sectional survey. Drug Des Devel Ther. 2018;12:1659–1668.
   PubMed Web of Science ®Google Scholar
• Yang L, Li G. IV3000透明敷贴联合水胶体敷料治疗PICC相关性皮肤过敏的效果观察 [observation on the effect of IV3000 transparent dressing combined with hydrocolloid dressing in the treatment of PICC-related skin allergy]. Contemporary Nursing. 2020;27:127–128.
   Google Scholar
• Wen X. 如何预防和治疗低血压 [How to prevent and treat hypotension] [Internet]. 大众健康报 [Popular Health News]; 2020. [cited 2022 Jan 04]. Available from: http://zkbctech.com/article/1852/2360.html.
   Google Scholar
• Lin S, Chen H. 舒血宁联合葛根素治疗不稳定型心绞痛的临床疗效评价 [evaluation of clinical efficacy of Shuxuening injection combined with puerarin in the treatment of coronary heart disease with unstable angina pectoris]. Chin J Prim Med Pharm. 2018;25:2628–2631.
   Google Scholar
• Wu C, Gong Y, Wu J, et al. Chinese version of the EQ-5D preference weights: applicability in a Chinese general population. PLOS One. 2016;11(10):e0164334.
   PubMed Web of Science ®Google Scholar
• Strauss WE, Auerbach M. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat Outcome Meas. 2018;9:285–298.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Pharmacoeconomic review report: iron isomaltoside 1000 (monoferric) (pharmacosmos a/S). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2020.
   Google Scholar
• Davies EW, Matza LS, Worth G, et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health Qual Life Outcomes. 2015;13:90.
   PubMed Web of Science ®Google Scholar
• Li C, Zhou H, Wang P. Health utility of type 2 diabetes patients using basal insulin in China: results from the beyond II study. Acta Diabetol. 2021;58(3):329–339.
   PubMed Web of Science ®Google Scholar
• Wehler E, Storm M, Kowal S, et al. PS1442 A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed/refractory acute myeloid leukemia. Poster session presented at: 36. Quality of life, palliative care, ethics and health economics. 23rd Congress of the European Hematology Association; 2018. Jun 14–17; Stockholm.
   Google Scholar
• Greenhawt M, Shaker M. Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction. JAMA Netw Open. 2019;2(12):e1918041.
   PubMed Web of Science ®Google Scholar
• Ronaldson S, Taylor M, Bech PG, et al. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children. Clinicoecon Outcomes Res. 2014;6:187–196.
   PubMedGoogle Scholar
• Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res. 2009;18(8):1095–1103.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guan H, Han S, et al. China guidelines for pharmacoeconomic evaluations: 2020. edition [Internet]. Chinese Pharmaceutical Association, China Society for Pharmacoeconomics and Outcomes Research and ISPOR Beijing Chapter; 2020 [cited 2022 Jan 04]. Available from: https://tools.ispor.org/PEguidelines/source/China-Guidelines-for-Pharmacoeconomic-Evaluations-2020.pdf.
   Google Scholar
• National Bureau of Statistics of China. Statistical communiqué of the People’s Republic of China on the 2020 national economic and social development. Beijing: National Bureau of Statistics of China; 2021.
   Google Scholar
• Thompson SG, Nixon RM. How sensitive are cost-effectiveness analyses to choice of parametric distributions? Med Decis Making. 2005;25(4):416–423.
   PubMed Web of Science ®Google Scholar
• Hu Z, Tao H, Shi A, et al. The efficacy and economic evaluation of Roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):411–418.
   PubMed Web of Science ®Google Scholar